Tacrolimus in refractory polymyositis with interstitial lung disease.
作者信息
Oddis C V, Sciurba F C, Elmagd K A, Starzl T E
出版信息
Lancet. 1999 May 22;353(9166):1762-3. doi: 10.1016/S0140-6736(99)01927-3.
Abstract
摘要
相似文献
1
Tacrolimus in refractory polymyositis with interstitial lung disease.他克莫司用于治疗伴有间质性肺病的难治性多发性肌炎。
Lancet. 1999 May 22;353(9166):1762-3. doi: 10.1016/S0140-6736(99)01927-3.
2
Comment on: The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis.评论：他克莫司在合并多发性肌炎或皮肌炎的间质性肺疾病患者中的疗效。
Rheumatology (Oxford). 2015 Jun;54(6):1128-9. doi: 10.1093/rheumatology/kev029. Epub 2015 Mar 31.
3
Comment on: The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis: reply.关于《他克莫司治疗间质性肺疾病合并多发性肌炎或皮肌炎患者的疗效：回复》的评论
Rheumatology (Oxford). 2015 Jun;54(6):1129. doi: 10.1093/rheumatology/kev033. Epub 2015 Mar 31.
4
Tacrolimus in idiopathic inflammatory myopathy-associated interstitial lung disease: defining roles and responders.他克莫司在特发性炎性肌病相关间质性肺疾病中的作用及反应者界定
Rheumatology (Oxford). 2015 Jan;54(1):3-4. doi: 10.1093/rheumatology/keu335. Epub 2014 Oct 22.
5
Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis.他克莫司治疗两名难治性间质性肺病合并多肌炎/皮肌炎患者取得良好疗效。
Clin Exp Rheumatol. 2005 Sep-Oct;23(5):707-10.
6
The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis.他克莫司治疗多发性肌炎/皮肌炎并发间质性肺疾病患者的疗效。
Rheumatology (Oxford). 2015 Jan;54(1):39-44. doi: 10.1093/rheumatology/keu166. Epub 2014 Apr 24.
7
[Tacrolimus-induced gynecomastia in a patient with polymyositis].
Med Clin (Barc). 2016 Mar 18;146(6):284-5. doi: 10.1016/j.medcli.2015.10.012. Epub 2015 Dec 8.
8
The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review.他克莫司治疗难治性皮肌炎/多肌炎患者的疗效：一项系统评价。
Clin Rheumatol. 2015 Dec;34(12):2097-103. doi: 10.1007/s10067-015-3065-0. Epub 2015 Sep 2.
9
Tacrolimus for antisynthetase syndrome with interstitial lung disease?
Eur Respir J. 2008 Jul;32(1):244-5; author reply 245-6. doi: 10.1183/09031936.00029708.
10
Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus.抗合成酶综合征继发的急性呼吸窘迫综合征使用他克莫司可逆转。
Eur Respir J. 2008 Jan;31(1):213-7. doi: 10.1183/09031936.00014707.
引用本文的文献
1
Utility of Myositis-Specific Autoantibodies for Treatment Selection in Myositis.肌炎特异性自身抗体在肌炎治疗选择中的应用
Curr Treatm Opt Rheumatol. 2022 Dec;8(4):105-116. doi: 10.1007/s40674-022-00198-1. Epub 2022 Sep 28.
2
Novel Therapeutic Approaches in Connective Tissue Disease-Associated Interstitial Lung Disease.结缔组织病相关间质性肺病的新型治疗方法
Semin Respir Crit Care Med. 2024 Jun;45(3):435-448. doi: 10.1055/s-0044-1786155. Epub 2024 May 13.
3
Clinical pearls and promising therapies in myositis.肌炎的临床要点和有前途的治疗方法。
Expert Rev Clin Immunol. 2023 Jul-Dec;19(7):797-811. doi: 10.1080/1744666X.2023.2212162. Epub 2023 May 18.
4
"Management of myositis associated interstitial lung disease".“肌炎相关间质性肺病的管理”。
Rheumatol Int. 2023 Jul;43(7):1209-1220. doi: 10.1007/s00296-023-05336-z. Epub 2023 May 1.
5
Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.利妥昔单抗治疗特发性炎性肌病患者的疗效和安全性：系统评价和荟萃分析。
Front Immunol. 2022 Dec 12;13:1051609. doi: 10.3389/fimmu.2022.1051609. eCollection 2022.
6
Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management.系统性自身免疫性风湿病的胸部受累：发病机制与治疗。
Clin Rev Allergy Immunol. 2022 Dec;63(3):472-489. doi: 10.1007/s12016-022-08926-0. Epub 2022 Mar 18.
7
Idiopathic inflammatory myopathies.特发性炎性肌病。
Nat Rev Dis Primers. 2021 Dec 2;7(1):87. doi: 10.1038/s41572-021-00325-7.
8
Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management.肌炎相关性间质性肺疾病：诊断与管理的综合方法。
Clin Exp Rheumatol. 2022 Feb;40(2):373-383. doi: 10.55563/clinexprheumatol/brvl1v. Epub 2021 Mar 25.
9
The Role of Immune Cells in the Pathogenesis of Idiopathic Inflammatory Myopathies.免疫细胞在特发性炎性肌病发病机制中的作用
Aging Dis. 2021 Feb 1;12(1):247-260. doi: 10.14336/AD.2020.0410. eCollection 2021 Feb.
10
Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications.炎性肌病：诊断、发病机制和治疗的最新进展，以及与 COVID-19 相关的影响。
Acta Myol. 2020 Dec 1;39(4):289-301. doi: 10.36185/2532-1900-032. eCollection 2020 Dec.
本文引用的文献
1
Cyclosporine, FK-506, rapamycin, and other immunomodulators.环孢素、他克莫司、雷帕霉素及其他免疫调节剂。
Rheum Dis Clin North Am. 1996 Feb;22(1):133-54. doi: 10.1016/s0889-857x(05)70266-0.
2
Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy.特发性炎性肌病的药物治疗：对泼尼松、硫唑嘌呤和甲氨蝶呤反应的预测因素及其疗效比较
Am J Med. 1993 Apr;94(4):379-87. doi: 10.1016/0002-9343(93)90148-i.
3
FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.FK506：一种用于治疗自身免疫性疾病的新型免疫抑制剂。匹兹堡大学的理论依据及初步临床经验
Springer Semin Immunopathol. 1993;14(4):323-44. doi: 10.1007/BF00192307.
4
Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis.间质性肺纤维化对多发性肌炎和皮肌炎预后的不良影响。
Semin Arthritis Rheum. 1988 Aug;18(1):29-37. doi: 10.1016/0049-0172(88)90032-7.
5
A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.特发性炎性肌病分类的新方法：肌炎特异性自身抗体可界定实用的同质性患者群体。
Medicine (Baltimore). 1991 Nov;70(6):360-74. doi: 10.1097/00005792-199111000-00002.
Zotero 插件